What is Ispire Technology's latest dividend and current dividend yield?

What does Ispire Technology do and what are its main business segments?

What guidance did Ispire Technology's management provide for the next earnings period?

What were the key takeaways from Ispire Technology's earnings call?

What is the market's earnings forecast for Ispire Technology next quarter?

What factors drove the changes in Ispire Technology's revenue and profit?

Did Ispire Technology beat or miss consensus estimates last quarter?

What were the key takeaways from Ispire Technology’s earnings call?

- **Strategic Pivot Success**: $6.6M net loss (vs. $8M YoY), 32% opex reduction, and 116% cash-to-revenue collection highlight financial turnaround. 
- **Growth Catalysts**: Malaysian facility expansion (80 lines) and age-gating tech partnership with Charlie's (2-3M monthly chips). 
- **Market Opportunity**: $100B U.S. e-cigarette market poised to reopen with FDA-authorized flavored products using IKE Tech. 
- **International Expansion**: Active regulatory discussions in Southeast Asia, Middle East, and U.K. for mandated age-gating. 
- **Upcoming Deal**: Strategic nicotine sector partnership to be announced, with CFO noting 'much greater financial impact' than Charlie's deal.

**【CEO Summary Section】**
- **Strategic Shift to Nicotine Sector**: Q2 revenue declined to $20.3M (from $41.8M YoY) due to intentional pivot away from lower-margin cannabis customers. Focus on high-quality nicotine clients improved cash collection (116% cash vs. revenue in 2025 vs. 67% in 2024) and reduced net loss to $6.6M (from $8M YoY). 
- **Operational Efficiency**: Burned only $1M in operating cash from April 2025 to end-2025, with operating expenses down 32% to $10.3M. Days sales outstanding improved by 8 days YoY.
- **Key Initiatives**: 
  - **Malaysian Facility Expansion**: 80 production lines planned (up from 6), positioning for China's e-cigarette industry exit. 
  - **Age-Gating Technology (IKE Tech)**: Blockchain-based solution with Charlie's partnership targeting FDA-authorized flavored e-cigarettes. Expected 2-3M monthly chip sales by Q3. 
  - **G-Mesh Technology**: Superconductive glass vaping hardware in discussions with major nicotine companies. 

**【CFO Financial Commentary】**
- **Revenue & Margins**: Q2 gross margin 17.1% (down from 18.5% YoY) due to lower-margin product mix. 
- **Balance Sheet**: Cash of $17.6M as of Dec 31, 2025 (down from $24.4M June 30, 2025). Operating cash flow used $5.2M in first half of FY2026 vs. $0.4M provided in FY2025. 
- **Liquidity**: $1M operating cash burn since April 2025, with trend expected to continue. 

**【Q&A Highlights】**
- **Retail Trends**: Major retailers like Walgreens reducing e-cigarette sales due to FDA restrictions, but strong demand for flavored products. IKE Tech's age-gating solution could unlock $100B U.S. market. 
- **Chinese Imports**: Surge in Q2 2025 exports driven by China's April 2026 VAT tax hike. U.S. enforcement efforts have minimal impact on illicit market. 
- **Technology Differentiation**: IKE Tech's blockchain-based age verification (1-minute verification vs. 5-12min competitors) and no PII transmission. 
- **Global Expansion**: Active discussions in Southeast Asia, Middle East, and U.K. for mandated age-gating. 
- **Upcoming Deal**: Strategic partnership with a leading nicotine company to be announced in coming weeks.

Ispire Technology Inc. (ISPR) Q2 2026 Earnings Call Transcript

- **Strategic Shift Success**: 39% opex reduction, $600K EBITDA, and 41% net loss improvement validate focus on nicotine.
- **Tech Differentiation**: Patented G-Mesh and IKE Tech solutions positioning for nicotine partnerships and global age-gating adoption.
- **Manufacturing Scale**: Malaysia expansion to 80 lines poised to drive ODM revenue growth.
- **Regulatory Momentum**: FDA favoring age-gating, with international markets likely leading U.S. adoption.
- **Risk Management**: Cautious cannabis approach until federal banking, balanced with diversified supply chain strategy.

**【CEO Summary】**
- **Revenue Decline & Strategic Shift**: Q1 2026 revenue dropped to $30.4M (from $39.3M YoY) due to deliberate exit from the cannabis market, focusing instead on high-quality nicotine customers.
- **Cost Efficiency**: Operating expenses reduced by 39% YoY to $7.8M, net loss improved to $3.3M (from $5.6M), and non-GAAP EBITDA turned positive at $600K.
- **Tech Innovations**: Progress on IKE Tech (blockchain-based age verification) and G-Mesh (next-gen vaping solutions), with active discussions with major nicotine companies.
- **Manufacturing Expansion**: Malaysian facility expansion to 80 production lines (from 6), expected to enhance ODM partnerships and revenue growth.

**【CFO Financial Commentary】**
- **Revenue & Margins**: Gross profit $5.1M (down from $7.7M YoY), gross margin 17% (19.5% YoY) due to lower-margin product mix.
- **Cash Flow Management**: $22.7M cash on hand, operating cash outflow $1.2M vs. $3.6M inflow YoY, reflecting disciplined expense control.
- **Balance Sheet Health**: AR reduced 30% YoY to $44.5M, net loss contraction 41% YoY.

**【Q&A Highlights】**
- **JUUL Patent Strategy**: Differentiated tech with own patents, positioning to capture post-JUUL licensing agreements.
- **Malaysian Licensing**: Interim license valid until Oct 2026; expect permanent license by end-2025, enabling full manufacturing capacity.
- **Regulatory Outlook**: FDA leaning towards age-gating as solution, with international markets (Europe/Asia) likely to adopt faster than U.S.
- **Cannabis Reinvestment**: Cautious on U.S. cannabis until federal banking/legal clarity, prioritizing timely-paying nicotine customers.
- **Supply Chain Resilience**: Diversifying beyond China with Malaysia,80-line facility; tariff changes would enable dual sourcing strategy.


Ispire Technology Inc. (ISPR) Q1 2026 Earnings Call Transcript

- **Strategic Shift to Nicotine**: 15% YoY revenue decline driven by pivot from cannabis to higher-margin nicotine sector, with European revenue up 13.6% to $74.5M.
- **Cost Efficiency**: $10.2M annualized expense savings, including 9.1% QoQ reduction in accounts receivable and 12% QoQ drop in G&A to $6.7M.
- **Malaysian Manufacturing Expansion**: 80 production lines planned to capitalize on global vaping demand, reducing North American reliance (down 48% YoY).
- **Regulatory Breakthrough**: First component PMTA for blockchain age verification technology filed, with FDA acceptance in 4 weeks; 2 countries may approve before U.S.
- **Cannabis Challenges**: Q4 2025 cannabis revenue at $12.3M (low point), with potential return if federal scheduling reforms occur.
- **ODM Growth**: $18M pipeline from U.K. deal, with next product iteration for late 2025.


**【CEO Summary Section】**
- **Strategic Pivot to Nicotine**: Revenue declined 15% YoY due to intentional shift away from cannabis to focus on higher-margin nicotine sector, with a strategic focus on quality customers and improved payment terms.
- **Cost Optimization**: Achieved $10.2 million annualized expense savings, including a 9.1% QoQ reduction in gross accounts receivable and 13.6% YoY growth in European revenue to $74.5 million.
- **Malaysian Manufacturing Expansion**: Plans for 80 production lines in Malaysia to capitalize on global precision dosing vaping demand, reducing reliance on North America (down 48% YoY to $32.6 million) and Asia Pacific (down 29% YoY to $12.3 million).
- **Regulatory Progress**: Filed first component PMTA for blockchain-based age verification technology (IKE Tech), receiving FDA acceptance in 4 weeks, with 2 unnamed countries moving faster than the U.S.
- **Cannabis Challenges**: Despite U.S. cannabis market size (~$30B), cash flow constraints and lack of federal legalization led to strategic exit, with Q4 2025 cannabis revenue at a low point but potential return if scheduling reforms occur.

**【CFO Financial Commentary】**
- **Revenue & Margins**: FY2025 revenue $127.5M (-17% YoY), gross margin 17.8% (-1.8% YoY) due to cannabis pivot. European revenue growth offset declines elsewhere.
- **Expense Management**: Operating expenses $60.5M (+43% YoY) driven by marketing and bad debt, but Q4 G&A down 12% QoQ to $6.7M. Net loss $39.2M (-4% YoY).
- **Liquidity**: Cash $24.4M (-30% YoY), working capital $0.4M. Operating cash flow used $7.4M (-59% YoY).

**【Q&A Key Highlights】**
- **Age Gating Technology**: FDA reviewing component PMTA on expedited basis; 2 countries outside U.S. may approve first. IP protected via patents in blockchain communication and data processing.
- **U.K. ODM Deal**: $18M pipeline from upgraded product launch, with next iteration planned for late 2025. Feedback positive, but initial version underperformed due to U.K. disposable ban.
- **Malaysia Expansion**: Third facility for up to 80 lines to meet demand from major tobacco companies diversifying supply chains. Regulatory approvals delaying full capacity.
- **Cannabis Outlook**: Q4 2025 cannabis revenue ($12.3M) seen as realistic run rate, with focus on high-quality customers and new product launches. Federal legalization could prompt re-entry.


Ispire Technology Inc. (ISPR) Q4 2025 Earnings Call Transcript

- **Revenue Resilience**: Despite 12.7% YoY decline, AR reduction to $60.4M signals financial discipline. Malaysia factory expansion to 80 lines positions for 700M pod/year capacity.
- **Regulatory Breakthrough**: FDA PMTA filing for blockchain age-gating tech could unlock $50B+ black-market conversion, with near-term international sales.
- **Tariff Mitigation Success**: Shift to FOB pricing and Malaysia manufacturing offsets 30% U.S. tariffs on China goods, reducing customer exposure.
- **Cannabis Innovation Lead**: Sprout device and Volt platform set new safety standards, attracting multi-state operators and global nicotine providers.
- **Liquidity Watch**: Cash $23.5M (down $10.9M YoY), negative working capital expected to reverse in Q4 with restructuring benefits.


**【CEO Key Highlights】**
- **Revenue Performance**: Q3 2025 revenue of $26.2M (-12.7% YoY) driven by reduced demand in North America (-28.9%) and Europe (-2.9%), partially offset by Malaysia manufacturing diversification.
- **Accounts Receivable Improvement**: AR reduced by $7.3M to $60.4M, with focus on high-quality customers and stricter collection policies.
- **Malaysia Expansion**: 80 production lines in Phase 2 factory, targeting 700M pod devices/year. Secured interim nicotine manufacturing license, final approval pending.
- **FDA Regulatory Progress**: Filed blockchain-based age-gating PMTA with FDA; if approved, could be first component PMTA, enabling modular integration in 100+ ENDS products.
- **Cannabis Innovation**: Launched Sprout device with Raw Garden, featuring advanced safety features for cannabis oil. Volt platform offers standardized pod system for industry-wide adoption.

**【CFO Financial Breakdown】**
- **Gross Margin**: 18.2% (Q3 2025) vs. 20.4% (Q3 2024), driven by higher COGS from Malaysia transition and tariffs.
- **Operating Expenses**: $15.4M (+30.5% YoY) due to stock-based comp, bad debt, and restructuring costs.
- **Liquidity**: $23.5M cash (down $10.9M YoY) with negative working capital of $2.1M, expected to improve in Q4.
- **Nine-Month Trends**: Revenue $107.4M (-6.3%), gross profit $20.2M (+5.2%), net loss $35.2M (-13.4%).

**【Q&A Key Takeaways】**
- **FDA Port Shopping Impact**: CEO estimates black-market vaping products represent 5-7x legal market size ($50-70B+). Age-gating tech could shift consumer preference to compliant products, with near-term opportunities outside U.S.
- **EU Disposable Ban Strategy**: Positioning pod systems (Aspire's strength) and refillable devices to capitalize on EU disposable ban. Malaysia capacity positioned to meet demand.
- **Tariff Mitigation**: Shifted pricing to FOB factory terms, reducing tariff exposure. Malaysia manufacturing costs offset by lower tariffs, with full cannabis hardware migration planned.
- **Competitive Advantage**: Malaysia's 0% U.S. tariffs vs. Indonesia (35%) and Vietnam (45%) provide cost leadership. Age-gating tech and cannabis hardware innovation differentiate from competitors.


Ispire Technology (ISPR)-12 May 25-2025 Q3 Earnings call transcript

- **Revenue resilience**: Q2 $41.8M flat YoY, with Europe (+53%) offsetting North America decline
- **Margin expansion**: 18.5% gross margin (vs. 15% YoY) from selective customer strategy
- **Africa growth**: 500+ retail locations in South Africa/Nigeria; 2,000+ store expansion target
- **$8M cost savings**: Global operational realignment reduces U.S. expenses
- **PMTA breakthrough**: April 2025 component PMTA submission targets $7B+ flavored product market
- **Cash flow positive**: $0.4M 6-month operating cash flow vs. -$20.2M YoY
- **Shareholder value**: $10M buyback program signals confidence in undervalued equity

**【CEO Summary Section】**
- Q2 2025 revenue: $41.8 million (0.3% YoY increase), driven by Europe (+53.2%) and Africa (+$2.6M from South Africa launch). 
- Gross margin improved to 18.5% (vs. 15% YoY), fueled by higher-margin product mix and selective customer strategy.
- Key milestones: 
  - BRKFST nicotine products launched in South Africa/Nigeria with 500+ retail locations
  - Malaysian regulatory approvals (import/export licenses) finalized
  - $10M stock buyback program announced
- Cost savings initiatives: $8M annual savings via global operational realignment (US → Malaysia/HK)
- PMTA pipeline: Component PMTA submission planned for April 2025; potential $7B+ market opportunity for age-gated flavored products

**【CFO Financial Commentary】**
- Q2 2025 financials: 
  - Revenue: $41.8M (flat YoY), with Europe ($24M) offsetting North America decline (-45.3%)
  - Gross profit: $7.7M (up 22% YoY)
  - Operating expenses: $15.1M (up 48% YoY) due to Malaysia expansion and R&D
  - Net loss: $8M (vs. $4M YoY)
  - Cash position: $34.4M (stable YoY)
- Cash flow: Operating cash flow turned positive ($0.4M for 6 months) vs. -$20.2M YoY
- Capital allocation: $10M buyback program to enhance shareholder value

**【Q&A Highlights】**
1. **Cannabis partnerships**: 
   - 3 MSO/SSO accounts now represent ~1/3 of pipeline
   - I-80 filling machine gaining traction with high-volume customers
2. **Europe market**: 
   - U.K. disposable ban driving shift to refillable pod systems
   - Open system portfolio aligned with regulatory trends
3. **Tariff risk**: 
   - Malaysia manufacturing diversifies supply chain to mitigate U.S. tariffs
4. **PMTA timeline**: 
   - Component PMTA submission in April 2025; first FDA-approved age-gating technology
   - Potential licensing revenue from $30B+ illicit U.S. market

Actual	-0.07	-0.11	-0.06	-0.1	-0.14	-0.19	-0.26	-0.06	-0.12
Forecast	0.01	-0.06	-0.09	-0.06	-0.07	-0.12	-0.14	-0.1	-0.01
Surprise	-800.00%	-83.33%	+33.33%	-66.67%	-100.00%	-58.33%	-85.71%	+40.00%	-1100.00%

Actual	41.69M	30.02M	37.32M	39.34M	41.83M	26.19M	20.13M	30.35M	20.29M
Forecast	48.00M	44.50M	34.25M	51.66M	38.65M	31.80M	22.40M	30.00M	32.80M
Surprise	-13.16%	-32.55%	+8.97%	-23.85%	+8.23%	-17.64%	-10.11%	+1.17%	-38.14%

ISPR

ISPR fundamentals

ISPR Q2 2026 Earnings

Earnings Call

You can ask Aime

ISPR

ISPR fundamentals

ISPR Q2 2026 Earnings

Earnings Call

ISPR Earnings Call Summary for Q2/20268:00 AM on Feb 6, 2026

ISPR Earnings Call Summary for Q1/20268:00 AM on Nov 6, 2025

ISPR Earnings Call Summary for Q4/20258:00 AM on Sep 16, 2025

ISPR Earnings Call Summary for Q3/20258:00 AM on May 12, 2025

ISPR Earnings Call Summary for Q2/20258:00 AM on Feb 10, 2025

You can ask Aime